ArticleNature communications2023
Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- FAAH initiates a positive feedback loop to promote lung adenocarcinoma progression through inhibition of ferroptosis.Cell death and differentiation · 2026Article
- Identification of breast cancer susceptibility genes via trans-ethnic Mendelian randomization and colocalization analyses.Medicine · 2025Article
- Caveolin-1: an ambiguous entity in breast cancer.Molecular cancer · 2025Review
- Article
- Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis.Advances in experimental medicine and biology · 2025Review
- Review
- Metabolic shifts in lipid utilization and reciprocal interactions within the lung metastatic niche of triple-negative breast cancer revealed by spatial multi-omics.Cell death & disease · 2024Article
- Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer.Journal of cannabis research · 2024Review
- Fatty acid amide hydrolase drives adult mammary gland development by promoting luminal cell differentiation.Cell death discovery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.